Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1b of Inhaled GB002 in Pulmonary Arterial Hypertension
NCT03926793Phase 1Completed
- Sponsor
- Gossamer Bio
- Start
- Feb 2020
- Primary completion
- May 2021
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 1, randomised, double-blind trial of seralutinib in pulmonary arterial hypertension (PAH) (5 arms), sponsored by Gossamer Bio. Primary endpoint: Number of participants with Treatment-Related Adverse Events at 200 days. Started Feb 2020; status: completed.
02
Drugs
seralutinib
03
Conditions
pulmonary arterial hypertension (PAH)
Beyond the preview
Go deeper on NCT03926793.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03926793.